Eli Lilly is a global pharmaceutical company with core franchises in diabetes, obesity, oncology, immunology, neuroscience and rare diseases. Market attention is centered on its GLP-1/GIP metabolic-drug portfolio, while pipeline progress, manufacturing capacity expansion and pricing/reimbursement policy remain key long-term variables.